EnteroBiotix receives MHRA MIA (IMP) licensure of state-of-the-art GMP manufacturing facility for producing microbiome therapeutics

Glasgow, Scotland – 11 October 2022 – EnteroBiotix Limited, the premier full-spectrum microbiome therapeutics company, today announced that it has been granted a Manufacturer’s licence for Investigational Medicinal Products (IMP) by the Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture microbiome product candidates for clinical trials. The facility also incorporates an in-house QC hub and analytical department.

Read full release